Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).
The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and
commercialization.
Commenting on the deal, Dr Christel Menet, Confo Therapeutics’ CSO, said: “This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project.”
Dr Michael Thompson, co-founder and CEO of DyNAbind added: “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target. ”
For more information please contact:
Confo Therapeutics
Dr Cedric Ververken, CEO | + 32 (0)9 261 0670 | info@confotherapeutics.com
For English-speaking and International Media:
Instinctif Partners for Confo Therapeutics
Dr Christelle Kerouedan, Sue Charles | + 44 (0)20 7457 2020 | confotherapeutics@instinctif.com
For Belgian Media:
Turnstone Communications for Confo Therapeutics
Dr Ann Van Gysel, Björn Debusschere | +32 9 218 71 97 | ann.vangysel@turnstone.be
About Confo Therapeutics
Confo Therapeutics is building a portfolio of first-in-class programs based on its proprietary Confo® technology which makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein
coupled receptors (GPCRs) in a particular conformation of interest as a superior starting point for drug discovery. GPCRs are attractive drug targets in the treatment of many different conditions, playing an essential part in numerous life processes and influencing diseases.
In addition to developing its own pipeline, Confo Therapeutics is entering into revenue-generating drug discovery partnerships with select pharma companies, on GPCR targets which do not compete with its internal projects. The Company has ongoing collaborations with Lundbeck and Roche. Confo Therapeutics was spun out of Vrije Universiteit Brussel and VIB in 2015 and has since raised over €36.7 million from an international investor syndicate (BioGeneration Ventures, Capricorn Venture Partners, Fund+, MINTS, Perceptive Advisors, PMV, QBIC, V-Bio Ventures, VIB and
Wellington Partners). More info: www.confotherapeutics.com